1
|
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, Ge J. Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study. J Clin Hypertens (Greenwich) 2024; 26:5-16. [PMID: 37667532 PMCID: PMC10795096 DOI: 10.1111/jch.14700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 07/02/2023] [Accepted: 07/03/2023] [Indexed: 09/06/2023]
Abstract
There lacks real-world study with a large sample size assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM-AML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OM-AML (20/5 mg) tablet were analyzed in the current prospective, single-arm, multi-center, real-world study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured. The mean (±SE) change of SeSBP/SeDBP was -10.8 ± 0.4/-6.6 ± 0.3 mmHg at W4 and -12.7 ± 0.5/-7.6 ± 0.3 mmHg at W8, respectively. At W4, 78.8% and 29.0% patients achieved BP target by China and American Heart Association (AHA) criteria; at W8, 84.7% and 36.5% patients reached blood pressure (BP) target by China and AHA criteria, accordingly. Meanwhile, 80.2% and 86.4% patients achieved BP response at W4 and W8, respectively. Home-measured SeSBP and SeDBP decreased from W1 to W8 (both p < .001). Besides, patients' and physicians' satisfaction were elevated at W8 compared with W0 (both p < .001). The medication possession rate was 94.8% from baseline to W4 and 91.3% from baseline to W8. The most common drug-related adverse events were nervous system disorders (4.6%), vascular disorders (2.6%), and general disorders and administration site conditions (2.3%) by system organ class, which were generally mild and manageable. In conclusion, OM-AML tablet is one of the best antihypertensive agents in patients with essential hypertension.
Collapse
Affiliation(s)
- Zhaoqiang Cui
- Department of CardiologyZhongshan Hospital, Fudan UniversityShanghaiChina
| | - Zhaohui Qiu
- Department of CardiologyShanghai Tongren HospitalShanghaiChina
| | - Wenli Cheng
- Department of CardiologyBeijing Anzhen Hospital, Capital Medical UniversityBeijingChina
| | - Wei Hu
- Department of CardiologyCentral Hospital of Minhang DistrictShanghaiChina
| | - Genshan Ma
- Department of CardiologyZhongda Hospital Affiliated to Southeast UniversityNanjingChina
| | - Xiaojun Cai
- Department of CardiologyJinan Central HospitalJinanChina
| | - Yafei Jin
- Department of CardiologyThe First Affiliated Hospital of Sun Yat‐sen UniversityGuangzhouChina
| | - Yi Zhao
- Department of CardiologyDalian Jinzhou First People's HospitalDalianChina
| | - Liqun He
- Department of CardiologyWuhan No. 1 HospitalWuhanChina
| | - Ying Li
- Department of CardiologyShanghai East HospitalShanghaiChina
| | - Peili Bu
- Department of CardiologyQilu Hospital of Shandong UniversityJinanChina
| | - Xiaoping Chen
- Department of CardiologyWest China Hospital of Sichuan UniversityChengduChina
| | - Ruxing Wang
- Department of CardiologyWuxi People's HospitalWuxiChina
| | - Lin Chen
- Department of CardiologyThird Affiliated Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| | - Peng Dong
- Department of CardiologyBeijing Aviation General HospitalBeijingChina
| | - Liuliu Feng
- Department of CardiologyShidong Hospital, Yangpu DistrictShanghaiChina
| | - Xuebin Han
- Department of CardiologyShanxi Cardiovascular Hospital (Shanxi Cardiovascular Diseases Institute)TaiyuanChina
| | - Mei Hong
- Department of CardiologyThe Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Yinglong Hou
- Department of CardiologyThe First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalJinanChina
| | - Minlei Liao
- Department of CardiologyBaoshan Branch, Shanghai General HospitalShanghaiChina
| | - Mingliang Wang
- Department of CardiologyPutuo People's Hospital, Tongji UniversityShanghaiChina
| | - Xiaoyan Wang
- Department of CardiologyWuxi Third People's HospitalWuxiChina
| | - Jianhong Xie
- Department of CardiologyZhejiang Provincial People's HospitalHangzhouChina
| | - Yawei Xu
- Department of CardiologyShanghai Tenth People's HospitalShanghaiChina
| | - Zhenxing Wang
- Department of CardiologyJiangsu Province Hospital of Chinese MedicineNanjingChina
| | - Kai Huang
- Department of CardiologyUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhanChina
| | - Yongle Li
- Department of CardiologyTianjin Medical University General HospitalTianjinChina
| | - Dongsheng Li
- Department of CardiologyWuhan Third HospitalWuhanChina
| | - Xiaojun Ji
- Department of CardiologyWenzhou Central HospitalWenzhouChina
| | - Jing Huang
- Department of CardiologyThe Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina
| | - Jun Wang
- Department of CardiologyJing'an District Central Hospital of ShanghaiShanghaiChina
| | - Danhong Fang
- Department of CardiologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
| | - Jian'an Wang
- Department of CardiologyThe Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouChina
| | - Lijiang Tang
- Department of CardiologyZhejiang HospitalHangzhouChina
| | - Yingwu Liu
- Department of CardiologyTianjin Third Central HospitalTianjinChina
| | - Guosheng Fu
- Department of CardiologySir Run Run Shaw Hospital of Zhejiang University School of MedicineHangzhouChina
| | - Juan Du
- Medical DepartmentDaiichi Sankyo (China) Holdings Co., LtdShanghaiChina
| | - Ling Wang
- Medical DepartmentDaiichi Sankyo (China) Holdings Co., LtdShanghaiChina
| | - Mengqi Liu
- Medical DepartmentDaiichi Sankyo (China) Holdings Co., LtdShanghaiChina
| | - Junbo Ge
- Department of CardiologyZhongshan Hospital, Fudan UniversityShanghaiChina
| |
Collapse
|
2
|
Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide. DRUGS & THERAPY PERSPECTIVES 2016. [DOI: 10.1007/s40267-016-0335-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|